Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Nov;50(11):3950-2.
doi: 10.1128/AAC.00337-06. Epub 2006 Sep 5.

Impact of sample size on the performance of multiple-model pharmacokinetic simulations

Vincent H Tam  1 , Samer Kabbara, Rosa F Yeh, Robert H Leary
Affiliations

Impact of sample size on the performance of multiple-model pharmacokinetic simulations

Vincent H Tam et al. Antimicrob Agents Chemother. 2006 Nov.

Abstract

Monte Carlo simulations are increasingly used to predict pharmacokinetic variability of antimicrobials in a population. We investigated the sample size necessary to provide robust pharmacokinetic predictions. To obtain reasonably robust predictions, a nonparametric model derived from a sample population size of >/=50 appears to be necessary as the input information.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ambrose, P. G., S. M. Bhavnani, and R. N. Jones. 2003. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob. Agents Chemother. 47:1643-1646. - PMC - PubMed
    1. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22. - PMC - PubMed
    1. Jelliffe, R., D. Bayard, M. Milman, M. Van Guilder, and A. Schumitzky. 2000. Achieving target goals most precisely using nonparametric compartmental models and “multiple model” design of dosage regimens. Ther. Drug Monit. 22:346-353. - PubMed
    1. Kuti, J. L., P. K. Dandekar, C. H. Nightingale, and D. P. Nicolau. 2003. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 43:1116-1123. - PubMed
    1. Kuti, J. L., N. R. Florea, C. H. Nightingale, and D. P. Nicolau. 2004. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Pharmacotherapy 24:8-15. - PubMed

Substances